T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production

Metastatic renal cell carcinoma (RCC) has a poor prognosis. Recent advances have shown beneficial responses to immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies. As only a subset of RCC patients respond, alternative strategies should be explored. Patients refractory to anti-PD-1 thera...

Descripción completa

Detalles Bibliográficos
Autores principales: van Asten, Saskia D., de Groot, Rosa, van Loenen, Marleen M., Castenmiller, Suzanne M., de Jong, Jeroen, Monkhorst, Kim, Haanen, John B.A.G., Amsen, Derk, Bex, Axel, Spaapen, Robbert M., Wolkers, Monika C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833735/
https://www.ncbi.nlm.nih.gov/pubmed/33537169
http://dx.doi.org/10.1080/2162402X.2020.1860482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833735/
https://www.ncbi.nlm.nih.gov/pubmed/33537169
http://dx.doi.org/10.1080/2162402X.2020.1860482

Ejemplares similares